

ACTIVITY REPORT

For the second quarter
of 2025



TCHAIKAPHARMA
HIGH QUALITY MEDICINES

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

28.07.2025

General information about Tchaikapharma High Quality Medicines Inc.

History and development of Tchaikapharma High Quality Medicines Inc.

Legal and commercial name

The legal and commercial name of the company is Tchaikapharma High Quality Medicines Inc.

Location and registration. Unique Identification Code (UIC)

The Company was listed in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company named TCHAIKA PHARMA INC.

By decision of the General Meeting of Shareholders from 04.07.2003, entered by Decision from 30.07.2003 on the company case 1096/2000 of the Varna District Court, the name was changed to TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

The Company is listed in the Commercial Register of the Registry Agency at the Ministry of Justice with **UIC 103524525**. With registered office. 1 G. M. Dimitrov Bld .

Foundation date and duration in time

The Company was founded and entered in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company. The duration of the Company is not limited in time.

Country of Company registration, headquarters and address pursuant to the Statute; legal form; legislation under which the Company operates

Tchaikapharma High Quality Medicines Inc. is a joint stock company which operates in compliance with the legislation of the Republic of Bulgaria.

The Company was incorporated in the Republic of Bulgaria.

The headquarters and registered office of the Company:

Republic of Bulgaria, 1172 Sofia, 1 G.M. Dimitrov Blvd.

Contact Address: 1172 Sofia, 1 G.M. Dimitrov Blvd.

Telephone: (359 2) 402 64 82

Internet site: www.tchaikapharma.com

Important events in the development of the business of the Company

Important events in the development of the Issuer for the last three years:

- Tchaikapharma High Quality Medicines Inc. was not transformed.

- Tchaikapharma High Quality Medicines Inc. was not transferred or pledged.
- There were no significant changes in the scope of activity of Tchaikapharma High Quality Medicines Inc.
- There were no filed claims for opening of insolvency proceedings.
- By Decision of the General Assembly of 20.06.2023 the profit of 2022 in the amount of BGN 2,791,019.53. (Two million seven hundred and ninety-one thousand nineteen leva and 53 st.) shall be allocated as follows BGN 271,101.95 (Two hundred and seventy one thousand one hundred and one levs and 95 sts.) to be allocated to reserves and BGN 2,499,194.65 (Two million four hundred and ninety nine thousand one hundred and ninety four levs and 65 sts.) to be allocated to Retained Earnings.
- By Decision of the General Assembly of 25.06.2024 the accumulated retained profit in the amount of BGN 7,707,502.56 (Seven million seven hundred and seven thousand five hundred and two levs and 56 st.) shall be distributed as follows: BGN 7,300,000 (Seven million and three hundred thousand levs) shall go for capital increase, reserves shall be set aside BGN 339,950.56 (Three hundred and thirty-nine thousand and nine hundred and fifty levs and 56 st.) and additional reserves BGN 7,552.30 (Seven thousand five hundred and fifty-two leva and 30 st.), BGN 60,000 (Sixty thousand leva) remains retained earnings.
- By Decision of the General Assembly of 25 June 2025, the profit for 2024 in the amount of BGN 4,491,886.82 (four million four hundred and ninety-one thousand eight hundred and eighty-six levs and 82 st.) shall be distributed as follows: BGN 449,188.68 (Four hundred and forty-nine thousand one hundred and eighty-eight levs and 68 st.) shall be allocated to reserves BGN 2,698.14 (Two thousand six hundred and ninety-eight levs and 65 st.) shall be allocated to additional reserves. The company's capital is increased by the amount of BGN 4,100,000, which includes the balance of the profit for 2024 in the amount of BGN 4,040,000.00 and the company's undistributed profit from previous years in the amount of BGN 60,000.00. The increase is in the process of being entered in the Commercial Register.
- The current capital of the Company is BGN 91,800,000 distributed in 91,800,000 ordinary dematerialized voting shares with a par value of BGN 1 (one) each.

Tchaikapharma High Quality Medicines Inc. is one of the fastest growing Bulgarian company specialized in manufacturing high quality and affordable generic and original medicines. The production facilities of the company are built in accordance with European requirements. The company is focused of quality and safety of the production of medicinal products for human medicine. In the years in which the company has been on the market it has proved its honesty and patient care.

Its main goal is the renewal of current trends in the worldwide drug therapy. The main priority for the company are medicinal products for the treatment of diabetes, diseases of the central nervous system, cancers and it is mainly focused on medications associated with the treatment of cardiovascular diseases.

Investments

Major investments for each of the following financial years: 2023, 2024 and 2025.

Overview of the investments in fixed assets by type and year is presented in the following table.

Investments for the period	2023	2024	2025
Tchaikapharma High Quality Medicines Inc.			
I. Fixed tangible assets	964	1 387	180
1. Land and buildings		34	
2. Property and equipment	957	1 351	179
3. Other fixed assets	7	2	1
II. Fixed intangible assets	417	10	103
1. Industrial property rights	417	6	92
2. Software		4	11
3. Patents and licenses			
Total amount of acquisition of fixed tangible and intangible assets	1 381	1 397	283

Major investments in progress

The company invested in the purchase of a machine for visual control of each vial in order to optimize the production process and faster release of the finished product. Installation at the Varna plant is complete and the machine is now in operation. At the end of 2024, the company began production of nutritional supplements.

Economic activity

The entered in the Commercial Register activity of the Company is: purchase of substances and formulations for the production and sale of pharmaceuticals in finished or processed form, (after Marketing Authorisation); primary and secondary packaging of formulations (after Marketing Authorisation); import, export, re-export and merchandising in original or processed form; barter transactions and commissions; commercial representation of foreign and domestic individuals and legal entities at home and abroad; industrial and commercial management; consulting, marketing, brokerage, leasing, licensing, entrepreneurship, transport and shipping, research and development activities.

Currently the main scope of activity of the Company can be summarized as follows:

- Production
- Packaging (primary and secondary)
- Marketing and promotion of medicines

– Research and Development

Tchaikapharma High Quality Medicines Inc. continuously maintains its production facilities in accordance with the contemporary European requirements for Good Manufacturing Practice in the production of medicines. At present, more than 160 medicinal products are produced in the company's factories. The premises and the equipment of the factories are executed in full compliance with the European requirements for the production of medicines and for the plant in Varna – also for sterile medicinal products.

Submitted documentation to BDA (Bulgarian Drug Agency):

Submitted applications for MA for new products: 2

Allopurinol-Tchaikapharma 100 mg; 300 mg tablets – MA - IAL-20086/14-05-2025;

IAL-20087/14-05-2025

Vale 24mg/26mg; 49mg/51mg; 97mg/103mg – MA - IAL-24995/17-06-2025

Submitted Renewals:

Submitted variations:

Bisor 5 mg; 10 mg tablets – Type IA - IAL-14167/01-04-2025

Ceftriaxon – Tchaikapharma 1g powder for solution for injection/infusion – Type IB - IAL-14163/01-04-2025

Cefotaxime-Tchaikapharma 1g powder for solution for injection – Type IB - IAL-14162/01-04-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets – Type IB - IAL-14422/03-04-2025

Co-Irbesso 150 mg/12,5 mg; 300 mg/12,5 mg film-coated tablets – Type IB - IAL-14349/02-04-2025

Cardifriend 5 mg; 10 mg tablets – Type IA - IAL-15441/09-04-2025

Cardifriend-Co 5mg/12,5 mg tablets – Type IA - IAL-15519/09-04-2025

Klacar XL 500 mg prolonged-release tablets – Type II - IAL16479/16-04-2025

Cefotaxime-Tchaikapharma powder for solution for injection 1g – Type IA - IAL-17144/23-04-2025

Kefadim, powder for solution for injection 1g – Type IA - IAL-17285/23-04-2025

Co-Hypertonic 50 mg/12,5 mg tablets - notif. Art 61 (3) - IAL-17018/22-04-2025

Co-Telsart 80 mg/12,5 mg; 80 mg/25 mg tablets - notif. Art 61 (3) - IAL-17020/22-04-2025;

IAL-17019/22-04-2025

Olsart 10 mg; 20 mg; 40 mg film-coated tablets - notif. Art 61 (3) - IAL-16941/22-04-2025;
IAL-16942/22-04-2025; IAL-16945/22-04-2025

Peximyr 0,18 mg; 0,7 mg tablets - notif. Art 61 (3) - IAL-17007/22-04-2025; IAL-17006/22-04-2025

Pizona Combi 15 mg/850 mg film-coated tablets - notif. Art 61 (3) - IAL-16961/22-04-2025

Pizona 15 mg; 30 mg; 45 mg tablets - notif. Art 61 (3) - IAL-16949/22-04-2025; IAL-16950/22-04-2025; IAL-16952/22-04-2025

PlaquEx Combi 75 mg/75 mg hard capsules - notif. Art 61 (3) - IAL-16960/22-04-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets - notif. Art 61 (3) - IAL-16928/22-04-2025

Tamayra Plus 5mg/5mg/12,5mg; 5mg/5mg/25mg; 10mg/5mg/25mg hard capsules - notif. Art 61 (3) - IAL-16963/22-04-2025; IAL-16964/22-04-2025; IAL-16966/22-04-2025

Co-Paxene 2 mg/0,625 mg; 4 mg/1,25 mg tablets - notif. Art 61 (3) - IAL-16957/22-04-2025;
IAL-16958/22-04-2025

Telsart 80 mg tablets - notif. Art 61 (3) - IAL-16954/22-04-2025

TromBye 100 mg tablets - notif. Art 61 (3) - IAL-16956/22-04-2025

Verapamil-Tchaikapharma 40 mg; 80 mg coated tablets - notif. Art 61 (3) - IAL/17011/22-04-2025; IAL-17013/22-04-2025

Verapamil-Tchaikapharma 240 mg prolonged-release tablets - notif. Art 61 (3) - IAL-16929/22-04-2025

Simvacor 10 mg; 20 mg; 40 mg film-coated tablets - notif. Art 61 (3) - IAL-17021/22-04-2025;
IAL-17022/22-04-2025; IAL-17024/22-04-2025

Klacar XL 500 mg prolonged-release tablets - notif. Art 61 (3) - IAL-16973/22-04-2025

Klacar 500 mg tablets - notif. Art 61 (3) - IAL-16955/22-04-2025

Lifurox 500 mg tablets - notif. Art 61 (3) - IAL-17003/22-04-2025

Levor 500 mg film-coated tablets - notif. Art 61 (3) - IAL-17033/22-04-2025

RosstaAcy 5 mg/100 mg; 10 mg/100 mg; 20 mg/100 mg hard capsules - notif. Art 61 (3) - IAL-16974/22-04-2025; IAL-16987/22-04-2025; IAL-16988/22-04-2025

Telmira 60mg; 90mg film-coated tablets - notif. Art 61 (3) - IAL-16932/22-04-2025

Metlinka 50 mg/850 mg; 50 mg/1000 mg film-coated tablets - notif. Art 61 (3) - IAL-16999/22-04-2025; IAL-17001/22-04-2025

ContaMedia 350mg/ml solution for injection - notif. Art 61 (3) - IAL-17022/22-04-2025

Akinestat 2 mg tablets - Type IB - IAL-17029/22-04-2025

Betablockade 50 mg; 100 mg prolonged-release tablets - Type IB - IAL-17030/22-04-2025

Jamax 5 mg tablets - Type IB - IAL-16946/22-04-2025

Vancocin CP 1 g powder for solution for infusion - group II; IB; IB; IB; IB; IB - IAL-17806/28-04-2025

ContaMedia 350mg/ml solution for injection - Type IA - IAL-17832/28-04-2025

ContaMedia 350mg/ml solution for injection - Type II - IAL-18313/30-04-2025

Buto-Asma 0,1 mg/dose pressurised inhalation, suspension - notif. Art 61 (3) - IAL-18503/02-05-2025

ParaCeta 500 mg tablets - notif. Art 61 (3) - IAL-18502/02-05-2025

Apiri 100 mg gastro-resistant tablets - notif. Art 61 (3) - IAL-18499/02-05-2025

Rivaroxaban- Tchaikapharma 10 mg; 15 mg; 20 mg film-coated tablets - notif. Art 61 (3) - IAL-18516/02-05-2025; IAL-18517/02-05-2025; IAL-18518/02-05-2025

AllDone 100 mg effervescent tablets - notif. Art 61 (3) - IAL-18513/02-05-2025

Sotapiryn 300mg/250 mg/2 mg efferecent tablets - notif. Art 61 (3) - IAL-18511/02-05-2025

Coolsart 20/12.5, 40/12.5 film-coated tablets - notif. Art 61 (3) - IAL-18507/02-05-2025; IAL-18508/02-05-2025

Letrofemin 2,5 mg film-coated tablets - notif. Art 61 (3) – IAL-18506/02-05-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets – Type IB - IAL-12128/08-05-2025

ParaCeta 500 mg tablets - notif. Art 61 (3) - IAL-19788/13-05-2025

Vorifungal 200 mg powder for solution for infusion – Type IB - IAL-19791/13-05-2025

Remifentanil-Tchaikapharma 5 mg solution for injection/infusion – Type IB - IAL-20992/21-05-2025

LanzAcid 30 mg gastro-resistant hard capsules - group IB; IB - IAL-21906/28-05-2025

Bisor 5 mg; 10 mg tablets - Type IAin – IAL-22574/30-05-2025

Sotapiryn, 300 mg/250mg/2 mg effervescent tablets – Type IA - IAL-24038/11-06-2025

Telmira 60mg; 90mg film-coated tablets - Type IB - IAL-24076/11-06-2025

LanzAcid 30 mg gastro-resistant hard capsules - Type IA - IAL-24297/12-06-2025

Jamax 5 mg tablets - notif. Art 61 (3) - IAL-25001/17-06-2025

Total: 57

Approved MA's from BDA:

Approved MA's for new products:

Approved Renewals: 1

MoriVid 200 mg film-coated tablets – renewal - BG/MA/MP-69228/26-06-2025

Approved variations:

Levor 500 mg film-coated tablets - Type IB - IAL-26399/26-06-2025

Verapamil-Tchaikapharma 80 mg coated tablets; 240 mg prolonged-release tablets - group IB; IB; IB; IA - IAL-24835/16-06-2025

Co-Telsart 80/25; 80/12.5 tablets – group IB; IB - IAL-14291/02-04-2025

Levor 5 mg/mL solution for infusion - group IB; IB - IAL-14140/01-04-2025

Oxaliplatin-Tchaikapharma 50 mg; 100 mg powder for solution for infusion - Type IB; IA in - BG/MA/MP-68410/07-04-2025; BG/MA/MP-68411/07-04-2025

Levor 5 mg/mL solution for infusion – group IB; IA - IAL-15561/10-04-2025

Levor 500 mg film-coated tablets - group IB; IA - IAL-15426/09-04-2025

Lifurox 1,5 mg powder for solution for injection/infusion - Type IB - IAL-19182/08.05.2025

Lifurox 750 mg powder for solution for injection/infusion - group IB; IB; IB - IAL-19192/08.05.2025

Sotapiryn, 300 mg/250mg/2 mg effervescent tablets - group IB; IB; IB - IAL-17398/24-04-2025

Bisor 5 mg; 10 mg tablets - Type IA - IAL-18359/30-04-2025

Ceftriaxon – Tchaikapharma 1g powder for solution for injection/infusion – Type IB - IAL-20047/14-05-2025

Cefotaxime-Tchaikapharma 1g powder for solution for injection – Type IB - IAL-19731/13-05-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets – Type IB - IAL-20397/16-05-2025

Co-Irbesso 150 mg/12,5 mg; 300 mg/12,5 mg film-coated tablets – Type IB - IAL-20224/15-05-2025

Cardifriend 5 mg; 10 mg tablets – Type IA - IAL-19450/09-05-2025

Cardifriend-Co 5mg/12,5 mg tablets – Type IA - IAL-19454/09-05-2025

Klacar XL 500 mg prolonged-release tablets - Type II - IAL-25028/17-06-2025

Cefotaxime-Tchaikapharma powder for solution for injection 1g – Type IA - IAL-19953/14-05-2025

Kefadim, powder for solution for injection 1g – Type IA - IAL-19955/14.05.2025

Co-Hypertonic 50 mg/12,5 mg tablets - notif. Art 61 (3) - IAL-24906/16-06-2025

Pizona 15 mg; 30 mg; 45 mg tablets - notif. Art 61 (3) - IAL-24402/12-06-2025;

IAL-24410/12-06-2025; IAL-24407/12-06-2025

PlaquEx Combi 75 mg/75 mg hard capsules - notif. Art 61 (3) - IAL-24850/16-06-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets - notif. Art 61 (3) - IAL-24856/16-06-2025

Tamayra Plus 5mg/5mg/12,5mg; 5mg/5mg/25mg; 10mg/5mg/25mg hard capsules - notif. Art 61 (3) - IAL-22983/04-06-2025; IAL-22984/04-06-2025; IAL-22985/04-06-2025

Co-Paxene 2 mg/0,625 mg; 4 mg/1,25 mg tablets - notif. Art 61 (3) - IAL-23191/04-06-2025; IAL-23192/04-06-2025

TromBye 100 mg tablets - notif. Art 61 (3) - IAL-24803/16-06-2025

Verapamil-Tchaikapharma 40 mg; 80 mg coated tablets - notif. Art 61 (3) - IAL-26957/30-06-2025; IAL-26962/30-06-2025

Verapamil-Tchaikapharma 240 mg prolonged-release tablets - notif. Art 61 (3) - IAL-24714/16-06-2025

Simvacor 10 mg; 20 mg; 40 mg film-coated tablets - notif. Art 61 (3) - IAL-26540/26-06-2025;

IAL-26544/26-06-2025; IAL-26547/26-06-2025

Klacar XL 500 mg prolonged-release tablets - notif. Art 61 (3) - IAL-23735/09-06-2025

Telmira 60mg; 90mg film-coated tablets - notif. Art 61 (3) - IAL-26959/30-06-2025;

IAL-26960/30-06-2025

Metlinka 50 mg/850 mg; 50 mg/1000 mg film-coated tablets - notif. Art 61 (3) - IAL-24838/16-06-2025; IAL24841/16-06-2025

Akinestat 2 mg tablets - Type IB - BG/MA/MP-69027/03-06-2025

Betablockade 50 mg; 100 mg prolonged-release tablets - Type IB - BG/MA/MP-69048/04-06-2025; BG/MA/MP-69049-04-06-2025

Jamax 5 mg tablets - Type IB - BG/MA/MP-69047/04-06-2025

Vancocin CP 1 g powder for solution for infusion - group II; IB; IB; IB; IB; IB - IAL-25952/23-06-2025

ContaMedia 350mg/ml solution for injection – Type IA - IAL-20600/19-05-2025

Buto-Asma 0,1 mg/dose pressurised inhalation, suspension - notif. Art 61 (3) - IAL-26953/30-06-2025

ParaCeta 500 mg tablets - notif. Art 61 (3) - IAL-26944/30-06-2025

Apiri 100 mg gastro-resistant tablets - notif. Art 61 (3) - IAL-26945/30-06-2025

AllDone 100 mg effervescent tablets - notif. Art 61 (3) - IAL-26567/27-06-2025

Coolsart 20/12.5, 40/12.5 film-coated tablets - notif. Art 61 (3) - IAL-26952/30-06-2025;
IAL-26950/30-06-2025

Sinepar 200 mg/ 50 mg prolonged-release tablets - Type IB - IAL-24219-12-06-2025

Vorifungal 200 mg powder for solution for infusion - Type IB - BG/MA/MP-68974/29-05-2025

LanzAcid 30 mg gastro-resistant hard capsules - group IB; IB - IAL-25031/17-06-2025

Bisor 5 mg; 10 mg tablets - Type IAin - IAL-23526/06-06-2025

LanzAcid 30 mg gastro-resistant hard capsules - Type IA - IAL-25066/17-06-2025

Total: 48

Kosovo

Submitted applications of MA's for new products:

Approved MA's for new products:

Submitted Renewals:

Approved Renewals:

Submitted variations:

Approved variations: 1

Rossta 10 mg; 20mg; 40mg film-coated tablets – type IAin - 22.4.2025

Employees

As of 30.06.2025 the average number of employees in Tchaikapharma High Quality Medicines Inc. was 216 (207 as of 31.12.2024). In the table below detailed information about the employees in the company is provided

	30.06.2025	Share
Number of employees as of 30.06.2025	216	100%
Higher education	138	64%
Secondary education	75	34%
Primary education	3	2%
Employees under 30 years	76	36%
Employees 31 - 40 years	81	37%
Employees 41 - 50 years.	48	22%
Employees 51 - 60 years.	11	5%
Employees 60+ years	0	0%
Women	108	50%
Men	108	50%

Significant events since the beginning of the year until 30.06.2025

In the second quarter of 2025 there were no significant events.

Key financial indicators

Indicators	01-06/2025 <i>BGN '000</i>	01-06/2024 <i>BGN '000</i>	Change %
Sales revenue	32 007	26 759	19.61%
Earnings before interest, taxes and depreciation (EBITDA)	6 733	4 620	45.73%
Net profit	4 785	2 807	70.46%
	01-06/2025 <i>BGN '000</i>	01-12/2024 <i>BGN '000</i>	Change %
Non-current assets	41 449	41 612	-0.39%
Current assets	90 213	86 892	3.82%
Equity	114 231	109 449	4.37%
Non-current liabilities	1 899	2 141	-11.3%
Current liabilities	15 529	16 914	-8.19%
	01-06/2025	01-06/2024	
EBITDA/Sales revenue	21%	17%	
Net profit/Sales revenue	15%	10%	

Review of the risk factors

- The Company's activities could be affected by any change in the regulatory requirements for the production of pharmaceutical products.

- Changes to the legislation regulating the Company's business are possible, and these can potentially increase the costs of compliance or have another effect on its operations.
- The production processes of the Company are subject to stringent requirements and approvals by regulatory authorities which may delay or interrupt the operations of the Company.
- The ability of the Company to pay dividends depends on a number of factors and there is no guarantee that in a year it will be able to pay dividends in accordance with its dividend policy.
- The Company is exposed to operational risk, which is inherent in its business activities.
- The Company is subject to multitude laws and regulations in the field of environmental protection and health and safety conditions and is exposed to potential liabilities related to the environment.
- The Company is exposed to strong competition.
- The Company operates in active exchange with foreign suppliers and customers. It is therefore exposed to currency risk, mainly against the US dollar. Currency risk is related to the adverse movement in the exchange rate of the US dollar against the Bulgarian lev in future business operations, recognized foreign currency assets and liabilities. The rest of the company's operations are usually denominated in Bulgarian lev and/or in euros.

Sales by types of dosage forms

Revenue by dosage forms	01-06/2025 <i>BGN '000</i>	01-06/2024 <i>BGN '000</i>
Tablets	25 642	21 125
Ampules	180	232
Vials	7 136	5 305
Total:	31 958	26 663

Revenue by therapeutic groups	01-06/2025 <i>BGN '000</i>	01-06/2024 <i>BGN '000</i>
Cardiovascular system	21 093	17 280
Musculoskeletal system and connective tissue	49	53
Respiratory system and antibiotics	3 182	3 236
Nervous system	437	351
Endocrine system	2 366	1 984
Other products	4 201	1 936
Digestive system and metabolism	1 119	1 565
Food supplements	257	-
Oncology	255	257
Total:	31 958	26 663

Changes in the inventories of products and work in progress	(47)	472
--	-------------	------------

Other operating income	01-06/2025	01-06/2024
	BGN '000	BGN '000
Income from rent	31	32
Other income	20	192
Total:	51	224

Financial income	01-06/2025	01-06/2025
	BGN '000	BGN '000
Income from interest	-	-
Income from exchange rate differences	59	18
Total:	59	18

Core activity expenses

Operating expenses	01-06/2025	01-06/2024
	BGN '000	BGN '000
Book value of sold products	1 836	1 218
Materials	7 419	6 697
External services	10 422	9 977
Salaries	4 428	3 757
Social security costs	829	718
Depreciation costs	1 385	1 258
Other	345	316
Total:	26 664	22 723

Cost of materials	01-06/2025	01-06/2024
	BGN '000	BGN '000
Basic material	6 590	6 118
Electricity	355	320
Fuels and lubricants	122	45
Spare parts and laboratory materials	143	96
Water	16	11
Other materials	193	107
Total:	7 419	6 697

Costs of external services	01-06/2025	01-06/2024
	BGN '000	BGN '000
Security	316	316
Insurance	13	14
Telephone and postage expenses	17	15
Equipment maintenance and subscription	110	136

Fees	156	171
Transport costs	24	22
Other costs for external services	9 786	9 303
Total:	10 422	9 977

Financial expenses	01-06/2025	01-06/2024
	<i>BGN '000</i>	<i>BGN '000</i>
Interest expenses	233	300
Expenses from exchange rate differences	45	61
Other financial expenses	11	13
Total:	289	374

Assets

	01-06/2025	01-12/2024
	<i>BGN '000</i>	<i>BGN '000</i>
Non-current assets		
Property, plant and equipment	32 359	33 304
Intangible assets	3 618	2 836
Investments with minority interest	69	69
Trade receivables	5 403	5 403
Total non-current assets	41 449	41 612

Current assets		
Inventories	16 605	15 862
Trade and other receivables	73 504	70 822
Treasury shares redeemed	-	129
Cash and cash equivalents	104	79
Total current assets	90 213	86 892
Total Assets	131 662	128 504

	01-06/2025	01-12/2024
	<i>BGN '000</i>	<i>BGN '000</i>
Property, plant and equipment		
Land and buildings	23 529	23 848
Machinery and equipment	8 504	9 167
Other	2	6
In the process of acquisition	324	283
	32 359	33 304

Inventories	01-06/2025	01-12/2024
	<i>BGN '000</i>	<i>BGN '000</i>
Materials	14 850	14 318
Production	201	265
Goods	1 554	1 279
Total:	16 605	15 862

Equity and liabilities

	01-06/2025 BGN '000	01-12/2024 BGN '000
Registered capital	91 800	91 800
Statutory reserve	13 097	13 097
Undistributed profit	9 337	4 552
Total Equity	114 234	109 449

Liabilities

	01-06/2025 BGN '000	01-12/2024 BGN '000
Non-current liabilities		
Long-term loans	433	675
Deferred tax liabilities	1 198	1 198
Liabilities to employees on retirement	268	268
Total non-current liabilities	1 899	2 141

Current liabilities

Trade and other liabilities	4 560	6 337
Short term loans	9 784	9 784
Current part of long-term loans	532	670
Other tax liabilities	653	123
Total current liabilities	15 529	16 914
Total liabilities	17 428	19 055
Total equity and liabilities	131 662	128 504

Financial indicators

	01-06/2025	01-12/2024
Leverage ratio	0.15	0.17
Financial autonomy ratio	6.55	5.74

Information on the shares of Tchaikapharma High Quality Medicines Inc.

The total amount of shares issued as of 30.06.2025 was 91,800,000 with a nominal value of BGN 1 per share. All issued shares are registered, dematerialized, ordinary and indivisible under the Statute of the Company. All issued shares are of the same type. Each share gives equal rights to its owner in proportion to the nominal value of the share. The shares of Tchaikapharma High Quality Medicines Inc. are traded on the official market of the Bulgarian Stock Exchange-Sofia.

Essential information on the shares of Tchaikapharma High Quality Medicines Inc.

	1-06/2025	1-12/2024
Total number of issued shares	91 800 000	91 800 000
Number of shares in circulation at end of period	91 800 000	91 800 000
Price per share at the end of the period in BGN	16.27	17.23
Market capitalization at the end of the period in BGN	1 493 586 000	1 581 714 000

Biser Georgiev

/Executive Director/

